SUTACIMIG
UNII 2QP8468SQP

Substance Identification & Data

This profile provides standardized clinical and technical data for Sutacimig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2QP8468SQP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2933972-64-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2QP8468SQP

CAS Registry Number

2933972-64-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SUTACIMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211722

National Cancer Institute reference terminology for clinical and research data.

INN ID

13275

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Sutacimig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Sutacimig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Sutacimig

Common Names & Synonyms

H-gamma4 heavy chain anti-F7a humanized (1-448) [VH (Homo sapiens IGHV4-30-2*07 (92.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [9.7.15] (26-34.52-58.97-111)) (1-122)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v10 CH3 L85.1, K88 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 L92 (311) (233-342), CH3 F85.1>L (407), R88>K (411) (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with L-kappa light chain humanized anti-F7a (1'-214') [V-KAPPA (Homo sapiens IGKV3D-11*01 (88.8%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; H-gamma4 heavy chain anti-TREML1 humanized (1''-440'') [VH (Homo sapiens IGHV3-74*01 (89.7%) -(IGHD) -IGHJ5*01 (92.9%), CDR-IMGT [8.8.7] (26''-33''.51''-58''.97''-103'')) (1''-114'')-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10 (CH1 (115''-212''), hinge 1-12 S10>P (222'') (213''-224''), CH2 L92 (303'') (225''-334''), CH3 (335''-439''), CHS K2>del (440'')) (115''-440'')], (128''-219''')-disulfide with L-kappa light chain, anti-TREML1 humanized (1'''-219''') [V-KAPPA (Homo sapiens IGKV2-24*02 (91.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'''-37'''.55'''-57'''.94'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'''), V101 (196''')) (113'''-219''')];dimer (228-220'':231-223'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Immunoglobulin G4 [230-proline,407-leucine,411-lysine,de-C-terminal-lysine], bispecific, anti-(human blood-coagulation factor VIIa) (human-Mus musculus monoclonal 11F2 γ4-chain), disulfide with human-Mus musculus monoclonal 11F2 κ-chain, (228→220′),(231→223′)-bis(disulfide) with immunoglobulin G4 [222-proline,de-C-terminal lysine] anti-(human TREM-like transcript 1 protein) (human monoclonal 0012Hyb γ4-chain) disulfide with human-Mus musculus monoclonal 0012Hyb κ-chain

immunoglobulin (H-gamma4_L-kappa)_(H-gamma4_L-kappa), anti-[Homo sapiens F7 (coagulation factor 7, blood coagulation factor VII, coagulation serum prothrombin conversion accelerator) activated (F7a, F7A, FVIIa, FVIIA)] and anti-[Homo sapiens TREML1 (triggering receptor expressed on myeloid cells like 1, TREM-like transcript 1, TLT1, TLT-1)], humanized monoclonal antibody, bispecific, bivalent

sutacimig [INN]

External Clinical & Regulatory Resources

Previous UNII2QP218C90D

Next UNII2QPC2TO5HY